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Background: Bright light treatment is effective for seasonal affective disorder (SAD), although the mechanisms of
action are still unknown. We investigated whether transcranial bright light via the ear canals has an antidepressant
effect in the treatment of SAD.
Methods: During the four-week study period, 89 patients (67 females; 22 males, aged 22-65, mean ± SD age:
43.2 ± 10.9 years) suffering from SAD were randomized to receive a 12-min daily dose of photic energy of one of
three intensities (1 lumen/0.72 mW/cm2; 4 lumens/2.881 mW/cm2; 9 lumens/6.482 mW/cm2) via the ear canals.
The light was produced using light-emitting diodes. The severity of depressive symptoms was assessed with the
Hamilton Depression Rating Scale – Seasonal Affective Disorder (SIGH-SAD), the Hamilton Anxiety Rating Scale
(HAMA), and the Beck Depression Inventory (BDI). Cognitive performance was measured by the Trail Making Test
(TMT). The within-group and between-group changes in these variables throughout the study were analysed with
a repeated measures analysis of variance (ANOVA), whereas gender differences at baseline within the light groups
were analysed using Student’s t-tests.
Results: Patients in all three groups showed significant decreases in their BDI, HAMA, and SIGH-SAD scores. Response
rates, i.e., an at least 50% decrease of symptoms as measured by the BDI, were 74%-79% in the three treatment groups.
Corresponding variations for the SIGH-SAD and the HAMA were 35-45% and 47-62%, respectively. No intensity-based
dose-response relationships in the improvement of anxiety and depressive symptoms or cognitive performance
between treatment groups were observed. Approximately one in four patients experienced mild adverse effects,
of which the most common were headache, insomnia, and nausea.
Conclusions: These results suggests that transcranial bright light treatment may have antidepressant and anxiolytic
effect in SAD patients, as both self- and psychiatrist-rated depressive and anxiety symptoms decreased in all treatment
groups. These improvements are comparable to findings of earlier bright light studies that used conventional devices.
The lack of dose response may be due to a saturation effect above a certain light intensity threshold. Further studies
on the effects of transcranial bright light with an adequate placebo condition are needed.
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The seasonal pattern of recurrent episodes of depression is
known as seasonal affective disorder (SAD) [1-3]. The pre-
cise pathogenesis of SAD is uncertain, despite several ex-
planatory theories such as photoperiod and phase-shifted
circadian rhythms, neurotransmitter functions, and/or a
genetic basis [4,5]. Given the fact that winter SAD is far
more prevalent than summer SAD [2,6], the term SAD
usually refers to winter SAD and is used accordingly in this
article hereafter. Episodes of SAD are characterized by
typical and atypical depressive symptoms, i.e., lowered
mood, energy loss, excessive sleep with difficulty waking,
cravings for carbohydrates, weight gain, irritability, social
withdrawal, daytime fatigue, and loss of concentration
[7,8]. Cognitive functioning is also impaired in patients
suffering from SAD [9].
The prevalence of SAD varies from 0% to 9.7% in the
general population [6]. In Western Europe, e.g., Finland,
Germany, England, and the Netherlands, the prevalence
of SAD has been reported to be approximately 7.1%,
12.7%, 4.4%, and 3.3%, respectively [10,11]. Climatological,
geographical latitude, social, and cultural influences and
genetic factors have been reported to have an impact on
the prevalence of SAD [6,8,12].
Bright light therapy (BLT) has been found to be effective
in the treatment of SAD [13-15]. In a meta-analysis, the ef-
fect size for the reduction of depressive symptoms was 0.84
[16]. The antidepressant effect of BLT seems to be potenti-
ated by early morning administration [17]. According to
clinical guidelines, the recommended bright light exposure
for the treatment of SAD is 10,000 lux for 30 min per day
when traditional fluorescent light sources are used [18].
Lower-intensity short-wavelength LED light sources may be
comparably effective for the treatment of SAD [19].
The mechanism of action of BLT in the treatment of
SAD is under debate [20,21]. According to the prevailing
theory, the non-image forming (NIF) effects of light are
mediated by a retinal photoreceptor system [22-24].
Melanopsin (OPN4), which is found in the intrinsically
photosensitive retinal ganglion cells (ipRGCs), is mainly
responsible for this phototransduction [25,26]. However,
the classical visual photoreceptor systems have also been
shown to play important roles in the transmission of non-
visual photic responses in mammals [27]. Light-induced
neural signals from the ipRGCs are transmitted to the
suprachiasmatic nucleus (SCN) via the retinohypothalamic
tract (RHT), [28]. Recently, it has been reported that OPN4
gene variants may dispose some individuals to SAD [29].
However, potentially light sensitive opsins, e.g., melanop-
sin, encephalopsin (OPN3), and neuropsin (OPN5) have
also been found at the mRNA and/or protein level in sev-
eral areas of the human [30-32] and rodent brain [32-36].
Light seems to be able to penetrate the mammalian
brain [37], including the human brain [38]. Our recentfindings suggest that transcranial bright light (TBL) treat-
ment via the ear canals modulates the neural networks of
the human brain [39], improves cognitive performance in
healthy participants [40,41], alleviates symptoms of SAD
[42], and acutely affects cardiovascular autonomic regula-
tion [43]. Moreover, TBL stimulation from one side of the
skull seems to change the functional connectivity of the
human brain as measured by Quantitative Electroenceph-
alography (QEEG) and low resolution electromagnetic
tomography (LORETA) [38]. In addition, cortical photo-
stimulation seems to have effects on immunoregulation
on patients suffering from rheumatoid arthritis [44].
The effects of transcranially administered light are
unlikely to be mediated via the eyes for several reasons.
There is light-absorbing melanin in the back of the eye.
Conscious visual perception of light has not been reported
by any participants during transcranial illumination in an
earlier study, and no eyesight-induced changes in the
visual cortex were observed by fMRI [39]. Moreover, a
recently published study showed that transcranial bright
light administered in the evening does not suppress mela-
tonin secretion [45]. The ability of light to suppress mela-
tonin secretion is well-established to be mediated via the
RHT [46]. Thus, we hypothesize that some effects of
external light are mediated via routes without the function
of the eyes.
The aim of this study was to investigate the effects of
TBL treatment administered via the ear canals on
depressive and anxiety symptoms in patients suffering
from SAD in a randomized, double-blind dose-response
study design.
Methods
The study was conducted during the darkest period of
the year (from the 24th of November to the 4th of
March) in northern Finland (latitude 65°N), where the
shortest daylight duration was less than 4 hours. Ninety
adults suffering from seasonal depressive symptoms
were recruited through advertisements in a local news-
paper and pre-screened for symptoms of SAD by a
phone interview. The experimental study design is pre-
sented in Figure 1. Structured diagnostic interviews were
conducted at week 0 and 4 by two trained psychiatrists.
The patients were instructed to avoid alcohol for 24 h and
coffee and other caffeine-rich drinks for 3 h preceding the
0- and 4-week measurements. The patients were also
instructed to go to bed no later than 11 PM the night be-
fore the 0- and 4-week measurements. All measurements
were conducted at approximately the same time of day to
minimize the influence of diurnal variation in the outcome
measurements. Ambient light was kept constant in the
research room during all visits. A diagnosis for recurrent
major depression (moderate or severe) according to the
Diagnostic and Statistical Manual of Mental Disorders
Figure 1 Randomized study procedures. A 12-minute bright light dose was administered transcranially via the ear canals daily after awakening. The
intensity of the transcranial bright light (TBL) was 1, 4 and 9 lumens in treatment groups 1, 2, and 3, respectively. Depressive symptoms were evaluated
using the SIGH-SAD, HAMA, and BDI measurements. Cognitive performance was measured using the Trail-Making Test (TMT) part A and B.
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Neuropsychiatric Interview (MINI) [47]. In addition,
patients had to fulfil the diagnostic criteria for “seasonal
pattern” [1].
Inclusion criteria were as follows: patients had to have a
score of at least 20 on the 29-item Structured Interview
Guide for the Hamilton Depression Rating Scale – Seasonal
Affective Disorder (SIGH-SAD) [48], a score of 10 or more
on the 21-item Hamilton Depression Rating Scale (HAMD),
and a score of 5 or more on the eight-item atypical symp-
tom score. Our inclusion criteria were analogous with the
criteria used for evaluating the response to treatment in
patients with SAD in previous studies [13,49]. Patients with
lifetime psychotic disorders, bipolar disorders, severe per-
sonality disorders, substance abuse or dependence, suicidal
ideation during the past month, any psychotropic medica-
tions, and other bright-light therapy for the current SAD
episode were excluded from this study. Pregnant females
were also excluded. Written informed consent was obtained
from the patients after they had been given a full description
of the study at the first visit. The research protocol was
approved by the Ethics Committee of Oulu University
Hospital, Finland, in compliance with the Declaration of
Helsinki. This study is registered with ClinicalTrials.gov,
number NCT01293409.
The bright light treatment was administered transcra-
nially via the ear canals using a bright light device (Valkee
Ltd., Oulu, Finland). The blue-enriched bright light wasTable 1 Radiometric and photometric comparisons of the ligh
Group Spectral characteristics Luminous flux (lumen) Illumina
1 λmax ≈ 448 nm 1 2386
2 λmax ≈ 448 nm 4 9542
3 λmax ≈ 448 nm 9 21470
Values are measured and calculated from one randomly selected light source. Illum
source. There were minor differences in the spectral compositions between light soproduced using two light-emitting diodes (LEDs), and was
transmitted into both ear canals by an optical fibre. The
patients were instructed to administer the TBL treatment
daily at home shortly after they normally awakened, and
always before noon. Based on an earlier study [42], the dur-
ation of the treatment was fixed to 12 minutes in the device
settings. Patients were carefully instructed to turn on the
treatment device only when the ear plugs were inserted in
the ear canal. After 12 minutes, the treatment device turned
off automatically. Subjects were not allowed to use any
other light therapy devices during the study period.
Patients were randomized into three groups: low dos-
age (group 1), intermediate dosage (group 2), and high
dosage TBL (group 3). The randomization process was
planned and implemented in practice by a person from
outside of the research group. Both the research team
and the patients were blind to the group assignment and
receiving active treatment. The luminous intensities of
the LEDs in the three groups were 1 lumen, 4 lumens,
and 9 lumens, respectively. Lumen is a unit for luminous
flux, which is defined as the total amount of visible light
emitted from a light source through a solid angle. The
corresponding irradiances (μW/cm2) and photon densities
(photons/cm2/s) are presented in Table 1. Figure 2 shows
the power spectra of the devices measured directly from a
distance of 1 cm.
The sum scores of the 21-item Beck Depression inventory
(BDI) [50], the 29-item SIGH-SAD, and the 14-itemt devices used in the three treatment groups
nce (lux) Irradiance (μW/cm2) Photon density (photons/cm2/s)
720 2.00 × 1015
2881 7.98 × 1015
6482 1.80 × 1016
inance and photon density are measured at a distance of 1 cm from the light
urces.
Figure 2 Spectral power distribution of the bright light produced by the light-emitting diode (LED) of the randomly selected device.
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Rating Scale (HAMA) [51] were used to evaluate the sever-
ity of SAD. The criterion for response was fulfilled when
the patient achieved a 50% or more decrease from the
baseline BDI, SIGH-SAD, and HAMA scores. The
remission rate was defined as a total score ≤ the cut-off and
the decrease of symptoms by 50% or more. The cut-off
used for the SIGH-SAD and the BDI in this study were 8
and 10, respectively. In addition, information about adverse
events related to the bright light treatment was recorded.
Cognitive functioning was measured by the Trail Making
Test (TMT) [52] at week 0 and 4. The TMT provides in-
formation on visual search, scanning, speed of processing,
mental flexibility, and executive functions [53]. The TMT
consists of two parts. In part A, the patient is asked to
draw lines to connect encircled numbers in a numerical
sequence (i.e., 1–2–3, etc.). In part B, the patient is
asked to draw lines to connect encircled numbers and
letters in an alternating numeric and alphabetic se-
quence (i.e., 1-A–2-B, etc.) as fast as possible [54]. The
score on each part represents the amount of time re-
quired to complete the task. The TMT-A test measures
attention and concentration while the TMT-B test mea-
sures mental flexibility [55].
All data are presented as percentages or as the mean and
95% confidence intervals. Student’s t-tests were used to
compare baseline values between genders within the light
treatment groups. Categorical variables were compared by
either a Chi-Square test or Fisher’s Exact test as appropri-
ate. The within-group and between-group changes in vari-
ables during the study were analysed with repeated
measures analysis of variance (ANOVA). Results with two-
tailed p-values <0.05 were considered statistically signifi-
cant. Statistical analyses were performed using SAS version
9.2 (SAS Institute Inc, Cary, NC, USA).Results
One patient was excluded from the study due to an
unexpected trip abroad (N = 89). The mean age ± SD of
the remaining patients was 43.0 ± 10.9 years (age range:
22 to 65 years). Subject characteristics were similar
across groups in most respects but differed for some var-
iables. Statistically significant differences were found for
the variables age (p = 0.0045) and BDI baseline sum
score (p = 0.0185) in treatment group 3 and for the
SIGH-SAD baseline sum score (p = 0.0414) in treatment
group 1 between females and males.
Depression scores
When compared to baseline (week 0), statistically signifi-
cant reductions were found for the mean BDI, SIGH-SAD,
and HAMA total scores after adjusting for age and gender
in each treatment group. Total scores in week 0 and 4 are
presented in Table 2. The percentage improvement mea-
sured by the BDI varied from 63% to 67% in the three
treatment groups. Corresponding variations for the SIGH-
SAD and the HAMA were 44%-47% and 47%-50%, re-
spectively (Table 3). There were no significant differences
in improvements between groups.
The percentages of the patients in each group who
achieved 50% or greater improvement in SAD symptoms
are shown in Figure 3. The response rates measured by the
BDI varied from 74% to 79% in the three treatment groups.
Corresponding variations for the SIGH-SAD and the
HAMA were 35-45% and 47-62%, respectively. Response
rates did not differ significantly across treatment groups.
Remission rates, as measured by self-rated BDI, ranged
from 71% to 79% in the three treatment groups (Table 4).
The corresponding variation for the SIGH-SAD ranged
from 13% to 29%. Remission rates did not differ signifi-
cantly across treatment groups.
Table 2 Depression and anxiety scale scores as measured
by the SIGH-SAD, HAMA, and BDI
Measure Group 1 (n = 28) Group 2 (n = 31) Group 3 (n = 30)
Mean 95% CI Mean 95% CI Mean 95% CI
SIGH-SAD
Week 0 36.6 34.1-39.0 36.1 33.7-38.5 35.7 33.5-37.8
Week 4 19.0 14.4-23.6 19.1 15.5-22.7 19.8 15.6-23.9
HAMD
Week 0 21.8 20.2-23.5 21.5 19.5-23.5 21.1 19.6-22.6
Week 4 11.3 8.5-14.1 11.1 9.0-13.1 11.5 8.9-14.0
Atypical score
Week 0 14.8 13.1-16.4 14.5 13.2-15.9 14.6 13.2-16.0
Week 4 7.7 5.3-10.1 8.0 6.2-9.9 8.3 6.3-10.3
HAMA
Week 0 23.6 21.3-26.0 22.6 20.2-25.1 22.1 19.9-24.2
Week 4 11.6 8.2-14.9 11.2 8.7-13.7 12.0 9.1-14.8
BDI
Week 0 20.6 17.5-23.7 18.9 15.8-22.1 19.3 15.8-22.9
Week 4 6.9 3.6-10.1 5.5 3.2-7.9 7.4 4.4-10.4
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tients’ depressive symptoms throughout the study (Figure 4).
A statistically significant decrease was found in each treat-
ment group after one week (time point week 1) when com-
pared with baseline, and the decrease in symptoms
continued throughout the study. There was no significant
difference between the reductions in depression scores
between treatment groups.
Cognitive performance
The cognitive performance of the patients, as measured
using the TMT-A, improved significantly in all three treat-
ment groups. On the TMT-B test, a significant improve-
ment in total time was observed in group 2 only. Total
performance times and absolute and percent improvements
are presented in Table 5 for all three treatment groups.
Adverse events
The percentage of patients who reported potential bright
light-related adverse events was 28.1% (n = 25). There
were no statistically significant differences in the presence
of bright light-related adverse events between treatment
groups. The most common adverse events reported wereTable 3 Improvement of symptoms as measured by the SIGH
Improvement Group 1 (n = 28) Group 2
% 95% CI p-value %
SIGH-SAD 47.4 34.9-60.0 0.0001 45.9
HAMA 49.9 34.7-65.2 0.0137 49.5
BDI 67.3 53.0-81.6 0.0158 67.4headache, insomnia, and nausea, which were reported by
10.1%, 5.6%, and 3.4% of the patients, respectively. In
addition, patients reported dizziness, earache, abnormal
sensation in the maxillary region, tinnitus, tiredness,
irregular heartbeat, and irritability. The total number of
different adverse events is presented in Table 6.Discussion
In the present study, both the self-rated and psychiatrist-
rated depressive and anxiety symptoms of SAD patients
decreased significantly during the four-week study period,
even after adjusting for age and gender. However, there
were no significant differences in the improvement of
depressive or anxiety symptoms between groups receiving
different intensities of bright light via the ear canals.
The mean decrease in BDI scores was 12.9 points
(66%), from a moderate depression level to a minimal
depression level [50], in the three treatment groups. The
psychiatrist-rated SIGH-SAD and HAMA scores de-
creased 16.8 points (46%) and 11.2 (49%), respectively.
HAMA scores decreased from a moderate anxiety level
to a normal level [51] during the four-week study period
in each treatment group.
Approximately three out of four (76%) patients in this
study fulfilled the BDI response criterion, which was de-
fined as a decrease of symptoms of at least 50%. The
mean SIGH-SAD and HAMA response rates were 39%
and 52% in the present study. Remission rate was
defined as a total score ≤ cut-off and a decrease of symp-
toms by 50% or more. The mean BDI remission rate was
75% for our study, whereas the SIGH-SAD remission
rate varied from 13% to 29% in the three treatment
group.
The alleviation of symptoms was somewhat lower in
the present study compared with our previous study
[42]. This result was due possibly to a greater placebo
response in the earlier study resulting from daily treat-
ment visits at the research center and the related
person-to-person interactions, which are known to play
a role in the placebo effect. Nonetheless, the significant
reduction in depressive and anxiety symptoms observed
in the present study parallels earlier studies that used
conventional bright light therapy devices and pharmaco-
logical therapy in the treatment of SAD and anxiety
[13,14,21,56-62].-SAD, HAMA, and BDI
(n = 31) Group 3 (n = 30)
95% CI p-value % 95% CI p-value
36.0-55.7 0.0001 43.7 32.7-54.8 0.0001
38.5-60.5 0.0056 46.5 35.9-57.2 0.0001
55.5-79.4 0.1282 63.2 49.9-76.6 0.0013
Figure 3 Response rates measured by SIGH-SAD, HAMA and BDI. Response rates are defined as the percentage of patients who met the
response criteria, i.e., a >50% decrease of symptom scores. Values are reported as% ± sem.
Jurvelin et al. BMC Psychiatry 2014, 14:288 Page 6 of 11
http://www.biomedcentral.com/1471-244X/14/288In earlier studies on patients suffering from SAD,
symptoms usually have been measured by inventories,
which concentrate on measurements of depression
domains. Because anxiety commonly co-occurs and has
a neurochemical similarity to depression [63], the meas-
urement of anxiety symptoms is justified in the present
study. The use of an anxiety measurement in this study
is a significant strength over earlier studies that have
investigated treatments for SAD.
The remission rates measured by the SIGH-SAD are
also slightly lower in the present study compared with
earlier bright light studies that used conventional bright
light treatment [13,21,59]. It is known that SAD patients,
who experience more severe symptoms, have lower
remission rates [64,65]. The mean total baseline score in
the present study was 36. Based on the assessment at
baseline, the SIGH-SAD score would have had to de-
crease by at least 28 points (78%) in order to fulfil our
previously defined criterion for remission (≤8). Thus, the
high baseline score may be partially responsible for the
low number of patients who met the criterion of remis-
sion for the SIGH-SAD in this study. In addition,Table 4 Remission rates as measured by the SIGH-SAD and B
Remission rate Group 1 (n = 28) Group
Proportion (%) 95% CI Propo
1SIGH-SAD 28.6 10.7-46.6 16.1
2BDI 78.6 63.1-94.1 71.0
1cut-off =8.
2cut-off =10.contrary to most of the earlier SAD studies, patients suf-
fering from bipolar disorder were excluded from this
study, which may have reduced the occurrence of spon-
taneous remissions.
Cognitive deficits are amongst the symptoms reported
for depression [9], and neuropsychological deficits in de-
pressed patients may be present themselves as impaired
performance, e.g., in attention and executive function
[66]. Earlier studies with pharmaceuticals [67] or con-
ventional bright light therapy [9] have reported deficits
in cognitive performance even after the remission of de-
pressive symptoms. In this study, cognitive performance
was found to improve significantly in all three treatment
groups measured by TMT-A, and for the medium dos-
age group for TMT-B. At the end of the four-week trial,
the time required to complete the tests were comparable
to the values of healthy individuals [53] in all groups.
The earlier findings on effect of TBL on cognitive perform-
ance in healthy subjects [40,41] were also observed after
treatment period of several weeks. In a recent study TBL
was not found to have an acute effect on reaction time [45]
suggesting that the improved cognitive performance foundDI
2 (n = 31) Group 3 (n = 30)
rtion (%) 95% CI Proportion (%) 95% CI
2.4-29.8 13.3 0.4-26.2
54.7-87.3 76.7 61.2-92.1
Figure 4 BDI sum scores during the four-week treatment period. Values are reported as the mean ± sem.
Jurvelin et al. BMC Psychiatry 2014, 14:288 Page 7 of 11
http://www.biomedcentral.com/1471-244X/14/288in this study is instead due to cumulative effect or associ-
ated with an improvement in depressive symptomatology.
The most common side effects observed in this study
were headache, insomnia, and nausea at a rate of 28%,
which is comparable to the rate reported in earlier bright
light studies using conventional bright light devices (e.g.,
25% [68]). In earlier studies that used conventional BLT,
the presence of headaches was slightly lower, whereas
insomnia and nausea were reported more often [68].
However, it is important to note that none of the
patients in the study stopped their participation due to
the presence of adverse effects.
One strength of our study is that we used both observe
rating SIGH-SAD and self-rating BDI to assess the severity
of depressive symptoms. SIGH-SAD as a sum of HAM-DTable 5 The time in seconds required to complete the Trail-m
Measure Group 1 (n = 28) Group 2 (n = 3
Mean (s) 95% CI (s) Mean (s)
TMT-A
Week 0 31.0 27.0-34.9 34.5
Week 4 27.0 23.3-30.7 27.1
TMT-B
Week 0 65.1 57.4-72.7 66.8
Week 4 59.7 49.4-70.0 56.6
Change % 95% CI p-value %
TMT-A −9.7 −2.2- -17.3 0.0066 −18.0
TMT-B −6.5 5.0- -18.1 0.1104 −11.2and atypical scores covers symptoms of both atypical and
melancholic depression, while atypical symptoms are far
less relevant in the BDI version used in this study [69].
HAM-D and BDI overlap on only half of the items. These
scales therefore rate different aspects of the disease and
thus poor concordance between scores might be pre-
dicted [70]. Patient or observer biases, severity of ill-
ness, age, education, sex, and personality variables
affect the level of correlation between observer and self-
rating scales [70-72]. These aforementioned issues may
cause differentiated scores on the SIGH-SAD and BDI
inventories. Thus, comparisons between scales should be
conducted with caution [70].
One limiting factor of our study is the lack of a proper
control group. The lack of a true placebo condition foraking test (TMT) part A and B
1) Group 3 (n = 30)





95% CI p-value % 95% CI p-value
−11.6- -24.4 <0.0001 −18.7 −12.3- -25.1 0.0004
−4.9- -17.4 0.0009 −7.9 −1.2- -16.9 0.1060
Table 6 The total amount of treatment-related adverse events
Adverse event Total emergence Amount in group1 Amount in group2 Amount in group3 p
Headache 9 4 3 2 ns
Insomnia 5 2 1 2 ns
Nausea 3 2 0 1 ns
Dizziness 2 0 1 1 ns
Tinnitus 2 1 0 1 ns
Tiredness 2 1 1 0 ns
Earache 3 0 1 2 ns
Irritation 1 0 1 0 ns
Abnormal sensation in the maxillary region 1 0 0 1 ns
Irregular heart beat 1 1 0 0 ns
Total 29 11 8 10 ns
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studying the effects of bright light therapy [57,73,74]. The
bright light used in this study was visible to the patients
even though it was administered using extra-visual routes
via the ear canals. Because the treatment was conducted
at home without supervision by the investigators, it was
not possible to create a proper placebo condition in this
study.
It is well known that bright light treatment is accom-
panied by a placebo response [14,75]. In meta-analysis
on earlier antidepressant studies the size of the placebo
effect was found to be 29.7% [76] and account for 68%
of the effect in the treatment group [77]. It is assumed
that sham devices have higher response rates than pla-
cebo pills in the treatment of depression [78]. However,
repetitive transcranial magnetic stimulation (rTMS) as a
non-pharmacological and transcranially administered
treatment has been found to elicit even lower placebo
response than pharmacological therapy in major depres-
sion [79]. In addition the subjects in this study were
severe depressed, which decreases the effect of placebo
[80]. Assuming that the placebo response of transcranial
bright light is in line with the placebo effect found in
earlier antidepressant studies, it is not likely that the
alleviation of the symptoms in this study would be
entirely explained by means of placebo effect. In future
studies, the size of the placebo response should be care-
fully scrutinized. In addition, inclusion of the follow-up
assessments after the end of the treatment would deliver
valuable information about the sustainability of the
induced effects on mood and cognition.
The improvements in anxiety and depressive symptoms
for the lowest dosage group paralleled the improvements
found in the other two dosage groups. Hence, a dose-
response relationship between the different light inten-
sities was not observed. The earlier findings concerning
intensity-based dose-response relationships of photother-
apy are contradictory. An intensity-based dose-responserelationship has been reported in earlier studies that used
conventional fluorescent bright light sources [81]. How-
ever, bright white light intensity of 250 lux has been found
to be as effective as 10000 lux when the light is adminis-
tered early in the morning [13,21]. In addition, the spectral
characteristics of light have been shown to influence the
effect of light treatment in SAD [19,82]. Blue-enriched
white-light (750 lux) and white light (10000 lux) have been
proven to be equally effective in alleviating SAD symp-
toms [57]. Blue-enriched light of even lower intensity
(98 lux) has also been shown to be effective in the treat-
ment of SAD [19]. Furthermore, a recent study has shown
that narrow-bandwidth blue light is effective in the treat-
ment of SAD [82]. Because illuminance measurements in
lux or lumens assume a photopic light sensitivity peaking
at 555 nm, the illuminance values given in lux or lumen
units underestimate the actual illuminance of blue-
enriched light sources. Based on the literature on the
wavelength-dependent effects of light in humans, a blue-
enriched light source was used in this study. It is not un-
reasonable to assume that the recently found extra-retinal
proteins such as melanopsin [83] have similar features as
the ones located in the retina and thus are also sensitive to
shorter wavelengths.
The light intensity at which the SAD light-therapy
response reaches saturation is still under discussion [57].
Based on the results from current studies that have used
blue-enriched light, the effect of light saturates at fairly
low light intensities [57]. The lack of a dose response in
therapeutic changes in the current study may therefore be
a consequence of the light saturation. This notion is sup-
ported by previous non-clinical bright light dose-response
studies that have shown that half of the maximum alerting
effect and phase resetting effect of a light pulse of 9100
lux can be achieved with 100 lux [84,85]. The data of
Chang et al. [86] have also shown that per minute of
exposure a 0.2-hr light pulse of 10000 lux was five times
more efficient in resetting the circadian pacemaker than a
Jurvelin et al. BMC Psychiatry 2014, 14:288 Page 9 of 11
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cent study failed to find a dose response between 10000
lux and 2000 lux bright light treatment on depression and
anxiety symptoms [87].
Another limiting factor of our study is that the dose
response was examined only as an intensity-dependent
variable, while the duration of treatment is also known
to have an effect on the response [88]. This latter effect
needs to be examined in a duration-based dose response
study. In addition, the exact timing of the treatment and a
detailed analysis of the sleep/wake cycles of patients was
not included in the current study. The only instructions
that the patients received regarding the timing of light
treatment was to administer the treatment shortly after
habitual wake time and before noon each day.
To date, there are no studies that describe the penetra-
tion of BLT to areas of the human brain, although there is
evidence that light is able to penetrate the skull [37,38].
The distance from the light source to the nearest brain
area is approximately 2 cm. The brain regions which
might encounter most of the light from the ear canal are
the anterior cerebellum, the inferior temporal lobe, and
the pons in the brainstem. The midbrain in the brainstem,
the posterior diencephalon, and the anterior occipital lobe
may also be within the range of the light photons, espe-
cially at longer wavelengths [39]. Haemoglobin and skin
melanin are the main absorbers of visible light [89], while
bone structures and many types of cells primarily scatter
light [90]. The relative absence of skin melanocytes and
the small amount of blood haemoglobin in the ear keeps
the light absorption in this design at a minimum before
entering brain tissue [39].
There is emerging evidence that at least some of the
non-image forming effects of bright light may be medi-
ated transcranially without affecting the eyes. However,
there are a limited number of studies that investigate
this issue. Furthermore, the findings of these studies are
preliminary and not all of them have been conducted in
a placebo setting. In addition, the putative role of the
brain opsins in phototransduction is still unknown.
Thus, the findings of this study should be interpreted
cautiously and further studies on the effects of transcra-
nial bright light with an adequate placebo condition are
needed.
Conclusions
In sum, the results of this study suggest that transcranial
bright light treatment may have antidepressant and anxio-
lytic effects on patients suffering from SAD. The present
results are comparable with the findings of previous bright
light studies that have used conventional bright light de-
vices or pharmaceuticals in the treatment of depressive
and anxiety symptoms. In future, studies on the efficacy
and mechanisms of action of transcranially administeredbright light are needed. Although the effects of transcra-
nial light are not likely to be mediated via the eyes, the
effects of TBL should also be studied in totally blind
people. Further studies are also needed to measure the
duration-based dose response.
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